NCT05914610

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Envolimab	Envolizumab 300mg, D1, ih, Q3W 4-6cycles
DRUG	Fruquintinib	Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
DRUG	Oxaliplatin	Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
DRUG	Tegafur	Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-07-30
• Completion: 2028-07-30
• First posted: 2023-06-22
• Last updated: 2023-08-25